Non-alcoholic fatty liver disease in primary health care
DOI:
https://doi.org/10.32385/rpmgf.v39i6.13546Keywords:
Non-alcoholic fatty liver, Primary health careAbstract
Introduction: The new epidemic of chronic liver disease is related to non-alcoholic fatty liver disease, which is increasing in parallel with the increase in obesity worldwide. The global prevalence is currently estimated at 24% and is more common in males. Most of these patients can be followed up in primary care, however, recent studies have shown insufficient knowledge about this pathology among primary care physicians and difficulty in identifying patients with significant fibrosis who need intervention on the part of the gastroenterologist.
Objective: The aim of this work is to review the approach to non-alcoholic fatty liver disease in primary health care.
Methods: To carry out this review article, a bibliographic search was carried out in the PubMed database in October 2021, using the MeSH terms ‘non-alcoholic fatty liver’ and ‘primary care’. Articles published between 2010 and 2021 were selected, written in Portuguese, English, or Spanish, and whose full text was available. One hundred and twenty-two results were obtained, considering in the final phase that only 22 fit the study objectives.
Results: Patients with this identified pathology should be evaluated for the stage of liver fibrosis, as this is the most difficult stage. Patients with advanced fibrosis are at risk of developing cirrhosis and hepatocellular carcinoma. There are numerous methods for diagnosing fibrosis in patients with diagnosed non-alcoholic fatty liver disease that can be applied in primary health care due to the use of serum values that are easy to obtain and inexpensive, allowing the calculation of easily accessible scores. Of the studied scores, they are recommended for the detection of advanced fibrosis FIB-4 and the NFS.
Conclusion: The suggestion of this study for approaching this pathology in primary health care involves the creation of a follow-up algorithm and referral of patients according to the values obtained by calculating the scores and clinical criteria.
Downloads
References
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20.
Agganis B, Lee D, Sepe T. Liver enzymes: no trivial elevations, even is asymptomatic. Cleve Clin J Med. 2018;85(8):612-7.
Pattison RJ, Esteban JP, Sempokuya T, Kewcharoen J, Kalathil S, Kuwada SK. Nonalcoholic fatty liver disease: an important consideration for primary care providers in Hawaii. Hawaii J Health Soc Welf. 2020;79(6):180-6.
Sanyal AJ. Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing? BMC Med. 2018;16(1):148.
Ngu JH, Goh GB, Poh Z, Soetikno R. Managing non-alcoholic fatty liver disease. Singapore Med J. 2016;57(7):368-71.
Caballeria L, Tóran P. Epidemia de esteatosis hepática: un análisis desde la atención primaria [The fatty liver epidemic: an analysis from the primary care]. Aten Primaria. 2019;51(9):525-6. Spanish
Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review. Liver Int. 2021;41(2):261-70.
Grgurevic I, Podrug K, Mikolasevic I, Kukla M, Madir A, Tsochatzis EA. Natural history of nonalcoholic fatty liver disease: implications for clinical practice and an individualized approach. Can J Gastroenterol Hepatol. 2020;2020:9181368.
Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, et al. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. Ann Hepatol. 2020;19(6):674-90.
Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, et al. Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Frontline Gastroenterol. 2017;8(4):252-9.
Samperio-González MA, Selvi-Blasco M, Manzano-Montero M, Méndez-Gómez J, Gil-Prades M, Azagra R. Prevalencia de la esteatosis hepática no alcohólica em población con hipertransaminasemia y grado de adecuación del diagnóstico registrado em atención primaria [Prevalence of non-alcoholic fatty liver disease in a population with elevated transaminases and level of accuracy of the diagnosis in primary care]. Aten Primaria. 2016;48(5):281-7. Spanish
Salva-Pastor N, Chávez-Tapia NC, Uribe M, Núño-Lámbarri N. The diagnostic and initial approach of the patient with non-alcoholic fatty liver disease: role of the primary care provider. Gastroenterol Hepatol Bed Bench. 2019;12(4):267-77.
Fowell AJ, Fancey K, Gamble K, Bicknell K, Dowman JK, Howden P, et al. Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease. Frontline Gastroenterol. 2020;12(2):102-7.
Caballería L, Auladell MA, Torán P, Pera G, Miranda D, Alumà A, et al. Risk factors associated with non-alcoholic fatty liver disease in subjects from primary care units: a case-control study. BMC Gastroenterol. 2008;8:44.
Armstrong MJ, Houlihan DD, Bentham L, Shaw JC, Cramb R, Olliff S, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol. 2012;56(1):234-40.
Srivastava A, Gailer R, Tanwar S, Trembling P, Parkes J, Rodger A, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71(2):371-8.
Ghevariya V, Sandar N, Patel K, Ghevariya R, Aron J, Anand S. Knowing what’s out there: awareness of non-alcoholic fatty liver disease. Front Med. 2014;1:4.
Kumar R, Teo EK, How CH, Wong TY, Ang TL. A practical clinical approach to liver fibrosis. Singapore Med J. 2018;59(12):628-33.
Zain SM, Tan HL, Mohamed Z, Chan WK, Mahadeva S, Basu RC, et al. Use of simple scoring systems for a public health approach in the management of non-alcoholic fatty liver disease patients. JGH Open. 2020;4(6):1155-61.
Yadav Y, Syn WK, Basu R. Evolving management strategies for nonalcoholic fatty liver disease-targeting primary care physicians. Diabetes Technol Ther. 2019;21(11):611-8.
Boursier J, Tsochatzis EA. Case-finding strategies in non-alcoholic fatty liver disease. JHEP Rep. 2020;3(2):100219.
Fabrellas N, Hernández R, Graupera I, Solà E, Ramos P, Martín N, et al. Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care: a population-based study. PLoS One. 2018;13(9):e0200656.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Portuguese Journal of Family Medicine and General Practice
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors will assign to the RPMGF the sole right to publish and distribute the content of the manuscript specified in this declaration via physical, electronic, broadcasting or any other medium that may come into existence. They also grant the RPMGF the right to use and exploit this manuscript, in particular by assigning, selling or licensing its content. This permission is permanent and takes effect from the moment the manuscript is submitted, has the maximum duration allowed by applicable Portuguese or international law and is of worldwide scope. The authors further declare that this assignment is made free of charge. If the RPMGF informs the authors that it is not going to publish their manuscript, the exclusive assignment of rights ceases forthwith.
The authors authorise the RPMGF (or any entity it may appoint) to act on their behalf when it believes that copyright may have been infringed.
